Cel Sci Corporation (CVM)

[rwa3848]

Standard of Care survival rates for Head & Neck Cancer max out around 10 months post treatment. Treatment becomes incrementally more toxic. It is, sadly, not outside the realm of possibility that the control group has already hit a high death number; thus leading to the withdrawal of IND enrollment amendment. If death rates in the MK group matched SOC, the FDA would have forced a study failure announcement rather than quibbling about Investigator Brochure details essential to potential fast track status (if this line of reasoning holds water)